

## **DCR/APDCRS Journal Club August Topic HPV/Anal CA**

### **A Pilot Study of the Immunological, Virological, and Pathological Consequences of Intra-Anal Imiquimod in HIV-1-infected Men with High-Grade Squamous Intraepithelial Lesions by Cranston et al.**

#### **Questions for Discussion**

1. How do you use Imiquimod for the treatment of patients with HGSIL?
2. What is the clinical relevance of different HPV subtypes?
3. What are the limitations with regard to the use of intra-anal imiquimod?
4. What factors must be considered when designing a pilot study with an off-label use for a medication?
5. How would you construct a follow-up study to this?

### **Condyloma Acuminatum, AIN and Anal Cancer in the Setting of HIV: Do We Really Understand the Risk? by Fazendin et al**

#### **Questions for Discussion**

1. With regard to screening strategies, what factors are important when determining how data from screening is applied?
2. When evaluating an at-risk population for screening, what parameters are important in order to determine prevalence?
3. What are the appropriate terms used to describe cytology in anal pathology?
4. Are issues of selection bias adequately addressed?
5. What limitations to retrospective reviews commonly demonstrate?

**Long-term Outcome of Ablation of Anal High-grade Squamous Intraepithelial Lesions:  
Recurrence and Incidence of Cancer by Goldstone et al**

**Questions for Discussion**

1. What techniques do you use to evaluate anal dysplasia and why?
2. Do you feel that this study has proved the goal of SCCA prevention? Why or why not?
3. What is the statistical relationship between HSIL and SCCA?
4. What are the potential downsides of routine HRA?
5. How do you assess potential conflicts of interest in a study?

**Salvage Surgery for Locoregional Failure in Anal Squamous Cell Carcinoma by Guerra et al**

**Questions for Discussion**

1. At what interval do you begin surveillance after completion of chemoradiation for treatment of SCCA? What method do you use, and what is your surveillance schedule?
2. What statistical method is used for survival assessment, and what other types of data can this be used to track?
3. When performing salvage surgery for APR, what technique do you use, and how do you address perineal closure?
4. Do the results of this paper make you want to change your management practice? If so, how and why?
5. What is your management approach to patients with recurrent disease in inguinal LN?
6. In your opinion, what are the biggest limitations to this paper? (Than those stated by the authors?)